52 results
8-K
EX-99.1
PYXS
Pyxis Oncology Inc
14 May 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
7:55am
conjugate (ADC) that uniquely targets EDB+FN within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression
424B2
PYXS
Pyxis Oncology Inc
3 Apr 24
Prospectus for primary offering
8:45pm
that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (“ADC”) that uniquely targets Extradomain-B Fibronectin (“EDB
8-K
EX-99.1
42nr9uqyefr1
27 Mar 24
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
7:49am
8-K
EX-99.1
s31o4lvhav
21 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
7:44am
8-K
EX-99.2
9h564zke
21 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
7:44am
8-K
EX-99.1
p2iyrrl
13 Mar 24
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
4:31pm
8-K
EX-99.1
yaiwsv8 hn
28 Nov 23
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
7:22am
424B3
w115610hd0 gbqu
30 Jun 23
Prospectus supplement
4:05pm
S-4/A
6ofhr1qup 6m2nefzrmb
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
u6yj h3mn
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
425
epnudc
30 May 23
Business combination disclosure
4:41pm
425
l9tzjammbx ooel0ai9
25 May 23
Business combination disclosure
8:14am
425
EX-99.1
8j316r5aalrnshjn
24 May 23
Business combination disclosure
4:55pm
8-K
EX-99.1
eqhlty8k
24 May 23
Regulation FD Disclosure
4:53pm